DRRX - デュレクト (DURECT Corporation) デュレクト

 DRRXのチャート


 DRRXの企業情報

symbol DRRx
会社名 Durect Corp (デュレクト)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ダレクト(Durect Corporation)は研究と開発に従事するバイオ医薬企業である。同社の候補製品は代謝/脂質障害向けの経口薬DUR-928、急性臓器傷害の注射可能薬DUR-928を含む。同社の他の製品候補はPOSIMIR(ブピバカインの制御放出注入)、REMOXY(経口制御放出オキシコドン)、ORADUR-ADHD、ELADUR(経口制御放出オキシコドン)、Relday(リスペリドン)、ORADURベースのオピオイド(ヒドロモルホン)、SABREベースの眼科薬を含む。同社のALZET製品ラインはマウス、ラットおよび他の実験動物の研究に使用される小型の移植可能な浸透圧ポンプと付属品を提供する。同社は製薬と医療機器クライアントの製品原材料に応用する標準およびカスタム生分解性ポリマーと賦形剤の生産と販売を行う。   デュレクトは米国の医薬品会社。慢性痛、術後疼痛、統合失調症、躁うつ症、注意欠陥多動性障害の治療薬に焦点を置く。「レモキシ―(経口オキシコドン)」、「ポジデュア(ブピバカイン注射剤)」、「エラデュア(経皮吸収ブピバカイン)」、リスペリドン系抗精神病薬、「オラデュア」の治験を行う。  
本社所在地 10260 Bubb Road Cupertino CA 95014 USA
代表者氏名 Felix D Theeuwes フェリックス・テューウィーズ
代表者役職名 Chairman Chief Scientific Officer
電話番号 +1 408-777-1417
設立年月日 35827
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数
url www.durect.com
nasdaq_url https://www.nasdaq.com/symbol/drrx
adr_tso
EBITDA EBITDA(百万ドル) 0.69000
終値(lastsale) 1.07
時価総額(marketcap) 173341767.64
時価総額 時価総額(百万ドル) 168.48170
売上高 売上高(百万ドル) 47.18500
企業価値(EV) 企業価値(EV)(百万ドル) 145.94370
当期純利益 当期純利益(百万ドル) -0.96200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 DURECT Corporation revenues decreased 22% to $6.9M. Net loss decreased 15% to $15.3M. Revenues reflect Product Revenues net decrease of 28% to $5.2M. Lower net loss reflects Other Research and development decrease of 22% to $12.4M (expense) Selling and general decrease of 13% to $5.4M (expense) Interest and other income increase from $75K to $398K (income).

 DRRXのテクニカル分析


 DRRXのニュース

   DURECT Corporation : Announces Proposed Offering of Common Stock | MarketScreener  2021/02/03 21:02:10 MarketScreener
CUPERTINO, Calif., Feb. 3, 2021 /PRNewswire/ -- DURECT Corporation , a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by… | February 3, 2021
   Durect stock soars 34% after it gets FDA approval for surgical pain treatment  2021/02/02 13:28:22 MarketWatch
Shares of Durect Corp. undefined gained 34.3% in premarket trading on Tuesday after the company said its drug, Posimer, had been approved by the Food and…
   Transdermal and Transmucosal Drug Delivery Systems Market - Awareness Insights 2025 | Aveva Drug Delivery Systems, 3M Pharmaceuticals, DURECT Corporation, ALZA Corporation  2021/01/06 10:38:53 OpenPR
Global Transdermal and Transmucosal Drug Delivery Systems Market: Snapshot Transdermal and transmucosal drug delivery systems as alternative drug delivery routes have gained traction in clinical practices over the past few decades. The need for these systems is driven by the growing
   DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million  2021/01/04 13:30:00 PR Newswire
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the sale of the LACTEL product line to Evonik closed and the $15 million payment was…
   North America Anti-Viral Therapies Markets, 2020-2027 - Strong Pipeline of Anti-viral Drugs and Growing Emphasis on Launching Anti-viral Agents  2020/11/09 22:30:00 Benzinga
DUBLIN , Nov. 9, 2020 /PRNewswire/ -- The "North America Anti-Viral Therapies Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type, Mechanism of Action, and Application, and Country" report has been added to ResearchAndMarkets.com's offering. The North America anti-viral therapies market is expected to reach US$ 31,092.80 million by 2027 from US$ 16,312.45 million in 2019; it is estimated to grow at a CAGR of 8.5% during 2020-2027. The anti-viral therapies market is growing primarily due to the increasing R&D expenditures by pharmaceutical companies and rising government support for research activities and clinical trials in North America . Additionally, strong pipeline of anti-viral drugs, and growing emphasis on launching anti-viral agents are likely to fuel the growth of the market during the forecast period. However, the high costs of drug development restrain the growth of the market. Antiviral therapy is one of the most exciting branches of virology. These therapies are based on several strategies - direct-acting antivirals target viral proteins, enzymes, or nucleic acids; passive antibodies neutralize circulating viruses; and several other antivirals target cellular proteins or processes essential for viral replication.
   Bioresorbable Medical Material Market 2020 Reflect Impressive Expansion by 2027 by Evonik. , Foster Corporation ,Poly-Med Corporation ,Zeus Industrial Products, Inc. ,Ashland ,Durect Corporation ,Groupe PCAS ,DSM ,Corbion ,Putnam Plastics  2020/10/06 15:03:14 OpenPR
A new research document with title Global Bioresorbable Medical Material Market Report covering detailed analysis, Competitive landscape, forecast and strategies has been added to the Insight Partners. The study covers geographic analysis that includes regions like North America, Europe and
   46 Stocks Moving in Tuesday's Pre-Market Session  2020/08/04 11:09:23 Benzinga
Gainers Alterity Therapeutics Limited (NASDAQ: ATHE ) shares rose 229% to $4.44 in pre-market trading after the company announced it will present at two upcoming conferences to report positive data for its treatment for Parkinson's Disorder MSA. Cocrystal Pharma, Inc. (NASDAQ: COCP ) rose 51.7% to $3.58 in pre-market trading after jumping 40% on Monday. Danaos Corporation (NYSE: DAC ) rose 29.5% to $4.70 in pre-market trading after the company reported better-than-expected Q2 results. YRC Worldwide Inc. (NASDAQ: YRCW ) rose 28.1% to $3.69 in pre-market trading after the company reported better-than-expected Q2 results. CHF Solutions, Inc. (NASDAQ: CHFS ) shares rose 25% to $1.25 in pre-market trading after climbing 18% on Monday. Ossen Innovation Co., Ltd. (NASDAQ: OSN ) rose 24.9% to $4.07 in pre-market trading. BlueLinx Holdings Inc. (NYSE: BXC ) rose 22.4% to $17.85 in pre-market trading following Q2 results. Verastem, Inc. (NASDAQ: VSTM ) rose 20.4% to $1.71 in pre-market trading after gaining 6% on Monday.
   The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings  2020/08/02 15:08:50 Benzinga
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.
   Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates  2020/05/11 22:55:07 Zacks Investment Research
Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -41.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Durect (DRRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release  2020/04/28 16:33:08 Zacks Investment Research
Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   46 Stocks Moving in Tuesday's Pre-Market Session  2020/08/04 11:09:23 Benzinga
Gainers Alterity Therapeutics Limited (NASDAQ: ATHE ) shares rose 229% to $4.44 in pre-market trading after the company announced it will present at two upcoming conferences to report positive data for its treatment for Parkinson's Disorder MSA. Cocrystal Pharma, Inc. (NASDAQ: COCP ) rose 51.7% to $3.58 in pre-market trading after jumping 40% on Monday. Danaos Corporation (NYSE: DAC ) rose 29.5% to $4.70 in pre-market trading after the company reported better-than-expected Q2 results. YRC Worldwide Inc. (NASDAQ: YRCW ) rose 28.1% to $3.69 in pre-market trading after the company reported better-than-expected Q2 results. CHF Solutions, Inc. (NASDAQ: CHFS ) shares rose 25% to $1.25 in pre-market trading after climbing 18% on Monday. Ossen Innovation Co., Ltd. (NASDAQ: OSN ) rose 24.9% to $4.07 in pre-market trading. BlueLinx Holdings Inc. (NYSE: BXC ) rose 22.4% to $17.85 in pre-market trading following Q2 results. Verastem, Inc. (NASDAQ: VSTM ) rose 20.4% to $1.71 in pre-market trading after gaining 6% on Monday.
   The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings  2020/08/02 15:08:50 Benzinga
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.
   Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates  2020/05/11 22:55:07 Zacks Investment Research
Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -41.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Durect (DRRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release  2020/04/28 16:33:08 Zacks Investment Research
Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis  2020/01/02 14:00:00 PR Newswire
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 デュレクト DRRX DURECT Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)